Molecular Profile |
Indication/Tumor Type |
Response Type |
Relevant Treatment Approaches |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
FGFR1 act mut
|
Advanced Solid Tumor
|
decreased response |
FGFR Inhibitor (Pan)
|
Nintedanib
|
Preclinical |
Actionable |
In a preclinical study, transformed cells expressing constitutively active FGFR1 demonstrated reduced sensitivity to Ofev (Nintedanib) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).
|
22238366
|
FGFR1 act mut
|
Advanced Solid Tumor
|
no benefit |
FGFR1 Inhibitor
|
Brivanib
|
Preclinical |
Actionable |
In a preclinical study, Brivanib (BMS-540215) did not inhibit receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366).
|
22238366
|
FGFR1 act mut
|
Advanced Solid Tumor
|
sensitive |
FGFR Inhibitor (Pan)
|
Ponatinib
|
Preclinical |
Actionable |
In a preclinical study, Iclusig (ponatinib) inhibited receptor phosphorylation and cell growth in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366).
|
22238366
|
FGFR1 act mut
|
Advanced Solid Tumor
|
decreased response |
|
Cediranib
|
Preclinical |
Actionable |
In a preclinical study, transformed cells expressing constitutively active FGFR1 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Cediranib (AZD-2171) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).
|
22238366
|
FGFR1 act mut
|
Advanced Solid Tumor
|
sensitive |
FGFR Inhibitor (Pan)
|
Erdafitinib
|
Phase I |
Actionable |
In a Phase I trial, Erdafitinib (JNJ-42756493) treatment resulted in stable disease in 70% (16/23) and partial response in 22% (5/23) of patients with advanced solid tumors harboring FGFR 1-4 activating mutations (including amplifications, mutations and translocations), while no antitumor activity was observed in patients with unknown or no known changes in FGFR (PMID: 26324363).
|
26324363
|
FGFR1 act mut
|
breast cancer
|
sensitive |
FGFR Inhibitor (Pan)
|
FIIN-01
|
Preclinical |
Actionable |
In a preclinical study, FIIN-01 inhibited Fgfr1 activation-induced proliferation and transformation of human breast epithelial cell lines in culture (PMID: 20338520).
|
20338520
|
FGFR1 act mut
|
Advanced Solid Tumor
|
sensitive |
FGFR1 Inhibitor
|
FF-284
|
Phase I |
Actionable |
In a Phase I trial, Debio 1347 (CH5183284) dosing regimen has been determined in solid tumor patients with activating FGFR1 alterations (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540).
|
detail...
|
FGFR1 act mut
|
Advanced Solid Tumor
|
sensitive |
FGFR Inhibitor (Pan)
|
Dovitinib
|
Preclinical |
Actionable |
In a preclinical study, Dovitinib (TKI258) inhibited receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366).
|
22238366
|